Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Resensitizing daclatasvir-resistant hepatitis C variants by allosteric modulation of NS5A.

Sun JH, O'Boyle DR 2nd, Fridell RA, Langley DR, Wang C, Roberts SB, Nower P, Johnson BM, Moulin F, Nophsker MJ, Wang YK, Liu M, Rigat K, Tu Y, Hewawasam P, Kadow J, Meanwell NA, Cockett M, Lemm JA, Kramer M, Belema M, Gao M.

Nature. 2015 Nov 12;527(7577):245-8. doi: 10.1038/nature15711. Epub 2015 Nov 4.

PMID:
26536115
2.

Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1 to 6: implications for cross-genotype activity.

Wang C, Jia L, O'Boyle DR 2nd, Sun JH, Rigat K, Valera L, Nower P, Huang X, Kienzle B, Roberts S, Gao M, Fridell RA.

Antimicrob Agents Chemother. 2014 Sep;58(9):5155-63. doi: 10.1128/AAC.02788-14. Epub 2014 Jun 16.

3.

Discovery and development of hepatitis C virus NS5A replication complex inhibitors.

Belema M, Lopez OD, Bender JA, Romine JL, St Laurent DR, Langley DR, Lemm JA, O'Boyle DR 2nd, Sun JH, Wang C, Fridell RA, Meanwell NA.

J Med Chem. 2014 Mar 13;57(5):1643-72. doi: 10.1021/jm401793m. Epub 2014 Feb 3.

PMID:
24621191
4.

Hepatitis C virus NS5A replication complex inhibitors: the discovery of daclatasvir.

Belema M, Nguyen VN, Bachand C, Deon DH, Goodrich JT, James CA, Lavoie R, Lopez OD, Martel A, Romine JL, Ruediger EH, Snyder LB, St Laurent DR, Yang F, Zhu J, Wong HS, Langley DR, Adams SP, Cantor GH, Chimalakonda A, Fura A, Johnson BM, Knipe JO, Parker DD, Santone KS, Fridell RA, Lemm JA, O'Boyle DR 2nd, Colonno RJ, Gao M, Meanwell NA, Hamann LG.

J Med Chem. 2014 Mar 13;57(5):2013-32. doi: 10.1021/jm401836p. Epub 2014 Feb 12.

PMID:
24521299
5.

Hepatitis C virus NS5A replication complex inhibitors. Part 6: Discovery of a novel and highly potent biarylimidazole chemotype with inhibitory activity toward genotypes 1a and 1b replicons.

Belema M, Nguyen VN, Romine JL, St Laurent DR, Lopez OD, Goodrich JT, Nower PT, O'Boyle DR 2nd, Lemm JA, Fridell RA, Gao M, Fang H, Krause RG, Wang YK, Oliver AJ, Good AC, Knipe JO, Meanwell NA, Snyder LB.

J Med Chem. 2014 Mar 13;57(5):1995-2012. doi: 10.1021/jm4016203. Epub 2014 Jan 17.

PMID:
24437689
6.

Characterizations of HCV NS5A replication complex inhibitors.

O'Boyle Ii DR, Sun JH, Nower PT, Lemm JA, Fridell RA, Wang C, Romine JL, Belema M, Nguyen VN, Laurent DR, Serrano-Wu M, Snyder LB, Meanwell NA, Langley DR, Gao M.

Virology. 2013 Sep;444(1-2):343-54. doi: 10.1016/j.virol.2013.06.032. Epub 2013 Jul 27.

7.

HCV NS5A replication complex inhibitors. Part 5: discovery of potent and pan-genotypic glycinamide cap derivatives.

Belema M, Nguyen VN, St Laurent DR, Lopez OD, Qiu Y, Good AC, Nower PT, Valera L, O'Boyle DR 2nd, Sun JH, Liu M, Fridell RA, Lemm JA, Gao M, Knipe JO, Meanwell NA, Snyder LB.

Bioorg Med Chem Lett. 2013 Aug 1;23(15):4428-35. doi: 10.1016/j.bmcl.2013.05.040. Epub 2013 May 23.

PMID:
23803586
8.

Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir.

Wang C, Sun JH, O'Boyle DR 2nd, Nower P, Valera L, Roberts S, Fridell RA, Gao M.

Antimicrob Agents Chemother. 2013 May;57(5):2054-65. doi: 10.1128/AAC.02494-12. Epub 2013 Feb 12.

9.

HCV NS5A replication complex inhibitors. Part 3: discovery of potent analogs with distinct core topologies.

Lopez OD, Nguyen VN, St Laurent DR, Belema M, Serrano-Wu MH, Goodrich JT, Yang F, Qiu Y, Ripka AS, Nower PT, Valera L, Liu M, O'Boyle DR 2nd, Sun JH, Fridell RA, Lemm JA, Gao M, Good AC, Meanwell NA, Snyder LB.

Bioorg Med Chem Lett. 2013 Feb 1;23(3):779-84. doi: 10.1016/j.bmcl.2012.11.086. Epub 2012 Dec 3.

PMID:
23273521
10.

Intragenic complementation of hepatitis C virus NS5A RNA replication-defective alleles.

Fridell RA, Valera L, Qiu D, Kirk MJ, Wang C, Gao M.

J Virol. 2013 Feb;87(4):2320-9. doi: 10.1128/JVI.02861-12. Epub 2012 Dec 12.

11.

In vitro activity of daclatasvir on hepatitis C virus genotype 3 NS5A.

Wang C, Valera L, Jia L, Kirk MJ, Gao M, Fridell RA.

Antimicrob Agents Chemother. 2013 Jan;57(1):611-3. doi: 10.1128/AAC.01874-12. Epub 2012 Oct 22.

12.

Synthesis and SAR studies of novel heteroaryl fused tetracyclic indole-diamide compounds: potent allosteric inhibitors of the hepatitis C virus NS5B polymerase.

Ding M, He F, Hudyma TW, Zheng X, Poss MA, Kadow JF, Beno BR, Rigat KL, Wang YK, Fridell RA, Lemm JA, Qiu D, Liu M, Voss S, Pelosi LA, Roberts SB, Gao M, Knipe J, Gentles RG.

Bioorg Med Chem Lett. 2012 Apr 15;22(8):2866-71. doi: 10.1016/j.bmcl.2012.02.063. Epub 2012 Mar 1.

PMID:
22424979
13.

Impact of a baseline polymorphism on the emergence of resistance to the hepatitis C virus nonstructural protein 5A replication complex inhibitor, BMS-790052.

Sun JH, O'Boyle Ii DR, Zhang Y, Wang C, Nower P, Valera L, Roberts S, Nettles RE, Fridell RA, Gao M.

Hepatology. 2012 Jun;55(6):1692-9. doi: 10.1002/hep.25581.

PMID:
22234905
14.

Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052.

Wang C, Huang H, Valera L, Sun JH, O'Boyle DR 2nd, Nower PT, Jia L, Qiu D, Huang X, Altaf A, Gao M, Fridell RA.

Antimicrob Agents Chemother. 2012 Mar;56(3):1350-8. doi: 10.1128/AAC.05977-11. Epub 2012 Jan 3.

15.

In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A.

Wang C, Jia L, Huang H, Qiu D, Valera L, Huang X, Sun JH, Nower PT, O'Boyle DR 2nd, Gao M, Fridell RA.

Antimicrob Agents Chemother. 2012 Mar;56(3):1588-90. doi: 10.1128/AAC.06169-11. Epub 2011 Dec 27.

16.

Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations.

Fridell RA, Wang C, Sun JH, O'Boyle DR 2nd, Nower P, Valera L, Qiu D, Roberts S, Huang X, Kienzle B, Bifano M, Nettles RE, Gao M.

Hepatology. 2011 Dec;54(6):1924-35. doi: 10.1002/hep.24594.

PMID:
21809362
17.

The synthesis of novel heteroaryl-fused 7,8,9,10-tetrahydro-6H-azepino[1,2-a]indoles, 4-oxo-2,3-dihydro-1H-[1,4]diazepino[1,7-a]indoles and 1,2,4,5-tetrahydro-[1,4]oxazepino[4,5-a]indoles. Effective inhibitors of HCV NS5B polymerase.

Ding M, He F, Poss MA, Rigat KL, Wang YK, Roberts SB, Qiu D, Fridell RA, Gao M, Gentles RG.

Org Biomol Chem. 2011 Oct 7;9(19):6654-62. doi: 10.1039/c1ob05525a. Epub 2011 Jul 28.

PMID:
21800000
18.

The effects of NS5A inhibitors on NS5A phosphorylation, polyprotein processing and localization.

Qiu D, Lemm JA, O'Boyle DR 2nd, Sun JH, Nower PT, Nguyen V, Hamann LG, Snyder LB, Deon DH, Ruediger E, Meanwell NA, Belema M, Gao M, Fridell RA.

J Gen Virol. 2011 Nov;92(Pt 11):2502-11. doi: 10.1099/vir.0.034801-0. Epub 2011 Jul 27.

PMID:
21795470
19.

Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052.

Fridell RA, Qiu D, Valera L, Wang C, Rose RE, Gao M.

J Virol. 2011 Jul;85(14):7312-20. doi: 10.1128/JVI.00253-11. Epub 2011 May 18.

20.

Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system.

Fridell RA, Qiu D, Wang C, Valera L, Gao M.

Antimicrob Agents Chemother. 2010 Sep;54(9):3641-50. doi: 10.1128/AAC.00556-10. Epub 2010 Jun 28.

21.

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect.

Gao M, Nettles RE, Belema M, Snyder LB, Nguyen VN, Fridell RA, Serrano-Wu MH, Langley DR, Sun JH, O'Boyle DR 2nd, Lemm JA, Wang C, Knipe JO, Chien C, Colonno RJ, Grasela DM, Meanwell NA, Hamann LG.

Nature. 2010 May 6;465(7294):96-100. doi: 10.1038/nature08960. Epub 2010 Apr 21.

PMID:
20410884
22.

A locus for autosomal dominant progressive non-syndromic hearing loss, DFNA27, is on chromosome 4q12-13.1.

Peters LM, Fridell RA, Boger ET, San Agustin TB, Madeo AC, Griffith AJ, Friedman TB, Morell RJ.

Clin Genet. 2008 Apr;73(4):367-72. doi: 10.1111/j.1399-0004.2008.00966.x. Epub 2008 Feb 13.

PMID:
18279434
23.

Myosin XVA expression in the pituitary and in other neuroendocrine tissues and tumors.

Lloyd RV, Vidal S, Jin L, Zhang S, Kovacs K, Horvath E, Scheithauer BW, Boger ET, Fridell RA, Friedman TB.

Am J Pathol. 2001 Oct;159(4):1375-82.

24.

The motor and tail regions of myosin XV are critical for normal structure and function of auditory and vestibular hair cells.

Anderson DW, Probst FJ, Belyantseva IA, Fridell RA, Beyer L, Martin DM, Wu D, Kachar B, Friedman TB, Raphael Y, Camper SA.

Hum Mol Genet. 2000 Jul 22;9(12):1729-38.

PMID:
10915760
25.

DFNB3 families and Shaker-2 mice: mutations in an unconventional myosin, myo 15.

Friedman TB, Hinnant JT, Fridell RA, Wilcox ER, Raphael Y, Camper SA.

Adv Otorhinolaryngol. 2000;56:131-44. Review. No abstract available.

PMID:
10868225
26.

Characterization of the human and mouse unconventional myosin XV genes responsible for hereditary deafness DFNB3 and shaker 2.

Liang Y, Wang A, Belyantseva IA, Anderson DW, Probst FJ, Barber TD, Miller W, Touchman JW, Jin L, Sullivan SL, Sellers JR, Camper SA, Lloyd RV, Kachar B, Friedman TB, Fridell RA.

Genomics. 1999 Nov 1;61(3):243-58.

PMID:
10552926
27.

Nucleocytoplasmic shuttling by protein nuclear import factors.

Truant R, Fridell RA, Benson ER, Herold A, Cullen BR.

Eur J Cell Biol. 1998 Dec;77(4):269-75.

PMID:
9930651
28.

Association of unconventional myosin MYO15 mutations with human nonsyndromic deafness DFNB3.

Wang A, Liang Y, Fridell RA, Probst FJ, Wilcox ER, Touchman JW, Morton CC, Morell RJ, Noben-Trauth K, Camper SA, Friedman TB.

Science. 1998 May 29;280(5368):1447-51.

29.

Correction of deafness in shaker-2 mice by an unconventional myosin in a BAC transgene.

Probst FJ, Fridell RA, Raphael Y, Saunders TL, Wang A, Liang Y, Morell RJ, Touchman JW, Lyons RH, Noben-Trauth K, Friedman TB, Camper SA.

Science. 1998 May 29;280(5368):1444-7.

30.
31.
32.

Nuclear import of hnRNP A1 is mediated by a novel cellular cofactor related to karyopherin-beta.

Fridell RA, Truant R, Thorne L, Benson RE, Cullen BR.

J Cell Sci. 1997 Jun;110 ( Pt 11):1325-31.

33.

HIV-1-induced cell fusion is mediated by multiple regions within both the viral envelope and the CCR-5 co-receptor.

Bieniasz PD, Fridell RA, Aramori I, Ferguson SS, Caron MG, Cullen BR.

EMBO J. 1997 May 15;16(10):2599-609.

34.

A nuclear role for the Fragile X mental retardation protein.

Fridell RA, Benson RE, Hua J, Bogerd HP, Cullen BR.

EMBO J. 1996 Oct 1;15(19):5408-14.

36.

Nuclear export of late HIV-1 mRNAs occurs via a cellular protein export pathway.

Fridell RA, Bogerd HP, Cullen BR.

Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4421-4.

37.

Amphibian transcription factor IIIA proteins contain a sequence element functionally equivalent to the nuclear export signal of human immunodeficiency virus type 1 Rev.

Fridell RA, Fischer U, L├╝hrmann R, Meyer BE, Meinkoth JL, Malim MH, Cullen BR.

Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):2936-40.

38.
39.

Identification of a novel cellular cofactor for the Rev/Rex class of retroviral regulatory proteins.

Bogerd HP, Fridell RA, Madore S, Cullen BR.

Cell. 1995 Aug 11;82(3):485-94.

40.
41.
42.

Identification of the activation domain of equine infectious anemia virus rev.

Fridell RA, Partin KM, Carpenter S, Cullen BR.

J Virol. 1993 Dec;67(12):7317-23.

43.
45.

Structure and transcription of the Drosophila melanogaster vermilion gene and several mutant alleles.

Searles LL, Ruth RS, Pret AM, Fridell RA, Ali AJ.

Mol Cell Biol. 1990 Apr;10(4):1423-31.

46.

Trypanosoma kansasensis sp. n. from Neotoma floridana in Kansas.

Upton SJ, Fridell RA, Tilley M.

J Wildl Dis. 1989 Jul;25(3):410-2.

PMID:
2668570
47.

The in vitro uptake of fluoride by secretory and maturation stage bovine enamel.

Fridell RA, Lussi A, Crenshaw MA, Bawden JW.

J Dent Res. 1988 Feb;67(2):487-90.

PMID:
11039063
48.

Absence of in-vitro fluoride-binding by the organic matrix of developing bovine enamel.

Lussi A, Fridell RA, Crenshaw MA, Bawden JW.

Arch Oral Biol. 1988;33(7):531-3.

PMID:
3245784

Supplemental Content

Loading ...
Support Center